Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: Structure-activity relationships

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2543-2555

  Tandon, Rashmi ^a,b   Ponnan, Prija ^a,b   Aggarwal, Neha ^b   Pathak, Rakesh ^a   Baghel, Anil S ^a   Gupta, Garima ^a   Arya, Anu ^b   Nath, Mahendra ^b   Parmar, Virinder S ^b   Raj, Hanumantharao G ^a   Prasad, Ashok K ^b   Bose, Mridula ^a  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Amino coumarins; Cell wall attacking; Multidrug resistant; Synergy

Indexed keywords

7 AMINO 4 METHYLCOUMARIN; COUMARIN DERIVATIVE; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; CELL WALL; COUMARINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ETHAMBUTOL; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; RIFAMPIN; STREPTOMYCIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80054684434     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr355     Document Type: Article

References (50)

1. WHO. Tuberculosis Fact Sheet No. 104. www.who.int/mediacentre/factsheets/fs104 (12 April 2011, date last accessed).
2. GreenFacts. Scientific Facts on Drug-Resistant Tuberculosis. http://www.greenfacts.org/en/tuberculosis/l-2/1-mdr-tb-xdr.htm (12 April 2011, date last accessed).
3. WHO. WHO Global Task Force Outlines Measures to Combat XDR-TB Worldwide. http://www.who.int/mediacentre/news/notes/2006/np29/en/index.html (12 April 2011, date last accessed).
4. The AIDS Control and Prevention (AIDSCAP) Project of Family Health International, The Francois-Xavier Bagnoud Center for Health and Human Rights of the Harvard School of Public Health, UNAIDS The Joint United Nation Programme on HIV/AIDS. The Status and Trends of the Global HIV/AIDS Pandemic. 1996. http://data.unaids.org/publications/IRC-pub04/statuskme_en.html (12 April 2011, date last accessed).
5. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull WHO 1992; 70: 515-26.
6. Raviglione MD, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-6.
7. Dye C, Scheele S, Dolin P et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-86.
8. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
9. Migliori GB, Espinal M, Danilova ID et al. Frequency of recurrence among MDR-TB cases successfully treated with standardized short-course chemotherapy. Int J Tubercul Lung Dis 2002; 6: 858-64.
10. Barry CE, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-55.
11. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-8.
12. Jarliera V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994; 123: 11-8.
13. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
14. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today 2006; 11: 21-7.
15. Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today 2008; 13: 1090-8.
16. Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006; 12: 179-85.
17. Gupta G. Studies on purification, characterization and molecular cloning of acetoxy drug: protein transacetylase from Mycobacterium smegmatis. Doctoral Thesis. University of Delhi, 2006; 1-115.
18. Atkins RL, Bliss DE. Substituted coumarins and aza coumarins. Synthesis and fluorescent properties. J Org Chem 1978; 43: 1975-80.
19. Franzblau SG, Witzig RS, McLaughlin JC et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998; 36: 362-6.
20. Hurdle JG, Lee RB, Budha NR et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008; 62: 1037-45.
21. Ho YII, Chan CY, Cheng AFB. In-vitro activities of aminoglycosideaminocyclitols against mycobacteria. J Antimicrob Chemother 1997; 40: 27-32.
22. Kone WM, Atindehou K, Terreaux C et al. Traditional medicine in North Cote-d'Ivoire: screening of 50 medicinal plants for antibacterial activity. J Ethnopharmacol 2004; 93: 43-9.
23. White EL, Suling WJ, Ross LJ et al. 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother 2002; 50: 111-4.
24. Matoba AY, Lee BL, Robinson NM et al. Combination drug testing of Mycobacterium chelonae. Investig Ophthalmol Vis Sci 1993; 34: 2786-9.
25. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
26. Weser DK, Ebert RH, Barclay WR et al. Studies on the metabolic significance of acid-fastness of tubercle bacilli. J Lab Clin Med 1953; 42: 828-9.
27. Koch-Weser D, Barclay WR, Ebert RH. The influence of isoniazid and streptomycin on acid-fastness, tetrazolium reduction, growth and survival of tubercle bacilli. Am Rev Tuberc 1955; 71: 556-65.
28. Winder FG, Collins PB. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 1970; 63: 41-8.
29. Takayama K, Wang L, David HL. Effect of isoniazid on the in-vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1972; 2: 29-35.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
31. Cheng A, Merz KM Jr. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J Med Chem 2003; 46: 3572-80.
32. Dixon SL, Merz KM Jr. One-dimensional molecular representations and similarity calculations: methodology and validation. J Med Chem 2001; 44: 3795-809.
33. Takayama K, Wang L, Merkal RS. Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid. Antimicrob Agents Chemother 1973; 4: 62-5.
34. Velayati AA, Farnia P, Ibrahim TA et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy 2009; 55: 303-7.
35. Hansch C, Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. New York: Wiley-Interscience, 1979.
36. Trnka L, Mison P, Bartmann K et al. Experimental evaluation of efficacy. In: Bartmann K, ed. Anti-tuberculosis Drugs. Berlin, Germany: Springer-Verlag, 1988; 31-232.
37. Jain NK, Surpal BB, Khanna SP et al. In vitro activity of ofloxacin against clinical isolates of Mycobacterium tuberculosis. Ind J Tub 1996; 43: 183-6.
38. Chen P, Gearhart J, Protopopova M et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006; 58: 332-7.
39. Reddy VM, Einck L, Andries K et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-6.
40. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 11: 2131-44.
41. Yee D, Valiquette C, Pelletier M et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7.
42. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-71.
43. Yee SW, Shah B, Simons C. Synthesis and antimycobacterial activity of 7-O-substituted-4-methyl-2H-2-chromenone derivatives vs. Mycobacterium tuberculosis. J Enzym Inhib Med Chem 2005; 20: 109-13.
44. Bardou F, Quemard AK, Dupont MA et al. Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins. Antimicrob Agents Chemother 1996; 40: 2459-67.
45. Bhatt A, Fujiwara N, Bhatt K et al. Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci USA 2007; 104: 5157-62.
46. Kubinyi H. Nonlinear dependence of biological activity on hydrophobic character: the bilinear model. Farmaco Sci 1979; 34: 248-76.
47. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971; 71: 525-616.
48. Appendino G, Mercalli E, Fuzzati N et al. Antimycobacterial coumarins from the Sardinian giant fennel (Ferula communis). J Nat Prod 2004; 67: 2108-10.
49. Stavri M, Mathew KT, Bucar F et al. Pangelin, an antimycobacterial coumarin from Ducrosia anethifolia. Planta Med 2003; 69: 956-9.
50. Virsdoia V, Shaikh MS, Manvar A et al. Screening for in-vitro antimycobacterial activity and 3-D QSAR study of 4-(arylamino)coumarin derivatives. Chem Biol Drug Des 2010; 76: 412-24.